Evidence mapPaperPMID 40579052Full record

ArticleJACC. Advances2025

Lifestyle Interventions in Cardiovascular-Kidney-Metabolic Syndrome JACC: Advances Expert Panel.

Izza Shahid, Jerrin Philip, Eleonora Avenatti, Deepika Laddu, Michael D Shapiro, Amit Khera, Ambarish Pandey, Chiadi E Ndumele, Martha Gulati, Khurram Nasir and 1 more

Abstract read
In one paragraph

Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Izza ShahidDivision of Preventive Cardiology, Houston Methodist Academic Institute, Houston, Texas, USA.
Jerrin PhilipDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Eleonora AvenattiDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Deepika LadduDepartment of Preventive Medicine, Northwestern University, Chicago, Illinois, USA.
Michael D ShapiroCenter for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Amit KheraDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ambarish PandeyDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Chiadi E NdumeleJohns Hopkins School of Medicine, Baltimore, Maryland, USA.
Martha GulatiBarbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Khurram NasirDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Kershaw V PatelDepartment of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: kvpatel@houstonmethodist.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular-kidney-metabolic (CKM) syndrome impacts nearly all organ systems, with progressive dysfunction leading to morbidity and mortality. The high burden of CKM syndrome requires accessible, scalable, and low-cost interventions to prevent downstream complications. Nonpharmacologic interventions targeting lifestyle factors, such as diet, physical activity, and behavioral modification, represent the cornerstone of CKM syndrome management to prevent a progressive disease and associated adverse outcomes. Lifestyle interventions play a key role not only in primordial and primary prevention in the earlier stages of CKM syndrome (stages 0-2) but also in subclinical cardiovascular disease (stage 3) as well as prevalent cardiovascular disease (stage 4). The purpose of the present review is to describe the evidence from randomized clinical trials for specific lifestyle interventions across CKM syndrome stages. This review will explore the impact of lifestyle interventions in each CKM syndrome stage and how they impact interrelated systems.

Indexed as

cardiovascular-kidney-metabolic syndromedietexercisenutritionprevention

Identifiers

PMID40579052
PMCPMC12277609

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.